Literature DB >> 19861450

Gene expression profiling for discovery of novel markers of minimal disease.

Virginie F Viprey, Susan A Burchill, Susan A Burchil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19861450      PMCID： PMC2871296          DOI： 10.1158/1078-0432.CCR-09-1601

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Authors:  Irene Y Cheung; Yi Feng; William Gerald; Nai-Kong V Cheung
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

2.  Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials.

Authors:  V F Viprey; M A Lastowska; M V Corrias; K Swerts; M S Jackson; S A Burchill
Journal:  J Pathol       Date:  2008-10       Impact factor: 7.996

3.  PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.

Authors:  Janine Stutterheim; Annemieke Gerritsen; Lily Zappeij-Kannegieter; Ilona Kleijn; Rob Dee; Lotty Hooft; Max M van Noesel; Marc Bierings; Frank Berthold; Rogier Versteeg; Huib N Caron; C Ellen van der Schoot; Godelieve A M Tytgat
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

4.  Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.

Authors:  Janine Stutterheim; Annemieke Gerritsen; Lily Zappeij-Kannegieter; Bilgehan Yalcin; Rob Dee; Max M van Noesel; Frank Berthold; Rogier Versteeg; Huib N Caron; C Ellen van der Schoot; Godelieve A M Tytgat
Journal:  Clin Chem       Date:  2009-05-21       Impact factor: 8.327

5.  Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET.

Authors:  Virginie F Viprey; Maria V Corrias; Bertil Kagedal; Silvestre Oltra; Katrien Swerts; Ales Vicha; Ruth Ladenstein; Susan A Burchill
Journal:  Eur J Cancer       Date:  2006-10-04       Impact factor: 9.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.